376 related articles for article (PubMed ID: 1724436)
21. [The place of bone marrow autografts in the treatment of Hodgkin's and non-Hodgkin's lymphoma].
Gisselbrecht C; Lepage E; Brice P; Trédaniel J; Gerota I
Nouv Rev Fr Hematol (1978); 1988; 30(1-2):131-4. PubMed ID: 2455276
[TBL] [Abstract][Full Text] [Related]
22. Avascular necrosis of the femoral head after treatment of Hodgkin's disease.
Tombolini V; Capua A; Pompili E
Acta Oncol; 1992; 31(1):64-5. PubMed ID: 1375043
[No Abstract] [Full Text] [Related]
23. Chemotherapy in the treatment of Hodgkin's disease.
Canellos GP; Come SE; Skarin AT
Semin Hematol; 1983 Jan; 20(1):1-24. PubMed ID: 6189191
[No Abstract] [Full Text] [Related]
24. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
[TBL] [Abstract][Full Text] [Related]
25. [Controversy regarding the treatment of Hodgkin's disease].
Balwierz W; Armata J
Pol Tyg Lek; 1989 Apr; 44(14):315-9. PubMed ID: 2482966
[No Abstract] [Full Text] [Related]
26. Immunoblastic lymphoma following therapy for Hodgkin's disease. A case report.
Casini M; Pianezze G; Fabris P; Cemin S; Coser P
Haematologica; 1986; 71(1):50-2. PubMed ID: 3084357
[No Abstract] [Full Text] [Related]
27. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
28. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
29. Detection of a dormant 20q- leukemia clone in bone marrow cultures with hematopoietic growth factors: implications for secondary leukemia post-transplant.
Redei I; Mangan KF; Ming PL; Mullaney MT; Rao PN; Goldberg SL; Klumpp TR
Bone Marrow Transplant; 1997 Mar; 19(5):521-3. PubMed ID: 9052924
[TBL] [Abstract][Full Text] [Related]
30. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
31. The role of chemotherapy in the management of early stage Hodgkin's disease.
Rosenberg SA
Hematol Oncol; 1984; 2(1):61-3. PubMed ID: 6203821
[No Abstract] [Full Text] [Related]
32. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
Andrieu JM; Colonna P
J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234
[No Abstract] [Full Text] [Related]
33. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program.
Klimo P; Connors JM
Semin Hematol; 1988 Apr; 25(2 Suppl 2):34-40. PubMed ID: 2456621
[TBL] [Abstract][Full Text] [Related]
34. Problems in Hodgkin's disease management.
Aisenberg AC
Blood; 1999 Feb; 93(3):761-79. PubMed ID: 9920825
[No Abstract] [Full Text] [Related]
35. Combination chemotherapy with alternating MOPP-ABVD in advanced Hodgkin's disease.
Brusamolino E; Lazzarino M; Morra E; Inverardi D; Merante S; Castelli G; Canevari A; Dornini G; Bernasconi C
Haematologica; 1989; 74(2):173-9. PubMed ID: 2473013
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy of Hodgkin's disease.
Carde P
Nouv Rev Fr Hematol (1978); 1990; 32(2):169-73. PubMed ID: 1696000
[TBL] [Abstract][Full Text] [Related]
37. [Improved survival rates in Hodgkin's disease].
Hayabuchi N; Jingu K; Miyoshi M; Hirata H; Masuda K; Shibuya T; Nishimura J; Komiyama S; Ishii E; Kikuchi M
Gan No Rinsho; 1988 Apr; 34(5):698-704. PubMed ID: 2455073
[TBL] [Abstract][Full Text] [Related]
38. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
[TBL] [Abstract][Full Text] [Related]
39. Pediatric Hodgkin's disease.
Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
[TBL] [Abstract][Full Text] [Related]
40. [Fatal Bacillus cereus sepsis and rhabdomyolysis in a patient with Hodgkin's disease].
Gómez-Herruz P; Gil-Fernández JJ; Guillen H; Arizcorreta A
Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):232-3. PubMed ID: 21324561
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
